Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis
Source abstract
Abstract
Unlabelled Drug-eluting stents (DESs), have shown promising results in prevention of in-stent restenosis after percutaneous coronary intervention (PCI). The elevated level of leukotrienes (LTs) detected in injured arteries after PCI, together with the potential role of LTs in inflammatory cascades and structural alterations in arterial wall provides the rationale for development of therapeutic strategies for prevention of in-stent restenosis using LTs receptor antagonists. Montelukast (MK) is a selective cysLT1 receptor antagonist, with anti-inflammatory and anti-proliferative properties, which has been used for treatment of various diseases. Here, we report on the fabrication of MK/PLGA particles by electrospraying, aiming towards the development of particle based coating of DESs. The electrosprayed particles incorporated with 3% and 6% w/w MK exhibited fairly spherical shape with smooth surfaces and narrow size distribution. Sustained release of MK for up to 40days was obtained for both formulations, with higher initial burst release and drug release rate for the particles with higher drug loading. The LTD4 induced proliferation and migration of human coronary artery smooth muscle cells (HCASMCs) by 35% and 85%, respectively, which was substantially antagonized using MK incorporated particles. Nevertheless, MK antagonism preserved the normal proliferation and migration of human coronary artery endothelial cells (HCAECs). Moreover, MK antagonism inhibited the LTD4 induced phenotypic transition of HCASMCs from contractile to synthetic type. The electrosprayed MK-PLGA particles can be employed as a coating for DESs to inhibit the formation of neointimal hyperplasia responsible for in-stent restenosis, yet preserve the healing rate of the stented vessel. Statement of significant Montelukast (MK) is a selective cysLT1 receptor antagonist, with anti-inflammatory and anti-proliferative properties. The LTD4 induced proliferation and migration of human coronary artery smooth muscle cells by 35% and 85%, respectively, which was substantially antagonized using MK incorporated particles. MK antagonism preserved the normal proliferation and migration of human coronary artery endothelial cells. The MK antagonism inhibited the phenotypic transition of human coronary artery smooth muscle cells from contractile to synthetic one induced by LTD4. The electrosprayed MK-PLGA particles can be employed as coating for DESs to inhibit formation of neointimal hyperplasia, responsible for in-stent restenosis.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Polymer Surface Interaction Studies · Nanoparticle-Based Drug Delivery · Electrospun Nanofibers in Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (53)
Show source-provided references
1. Drug-eluting stent: a review and update10.2147/vhrm.2005.1.4.263 ↗
2. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents10.1056/NEJM199604253341702 ↗
3. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy10.1016/S0735-1097(96)00450-0 ↗
4. Stents as a platform for drug delivery10.1517/17425247.2011.572068 ↗
5. Fabrication and controlled release of electrosprayed ReoPro-loaded metal surface for vascular stent10.1007/s13233-011-0516-6 ↗
6. A preliminary report on a novel electrospray technique for nanoparticle based biomedical implants coating: precision electrospraying10.1002/jbm.b.30641 ↗
7. Coaxial electrohydrodynamic atomization: microparticles for drug delivery applications10.1016/j.jconrel.2014.12.004 ↗
8. Electrosprayed enzyme coatings as bioinspired alternatives to bioceramic coatings for orthopedic and oral implants10.1002/adfm.200800819 ↗
9. In vitro responses to electrosprayed alkaline phosphatase/calcium phosphate composite coatings10.1016/j.actbio.2009.03.019 ↗
10. In vitro and in vivo reactivity of porous, electrosprayed calcium phosphate coatings10.1016/j.biomaterials.2006.01.052 ↗
11. Morphology of calcium phosphate coatings for biomedical applications deposited using electrostatic spray deposition10.1016/j.tsf.2005.11.116 ↗
12. Micro-/nanometer rough structure of a superhydrophobic biodegradable coating by electrospraying for initial anti-bioadhesion10.1002/adhm.201300021 ↗
13. Electrosprayed superhydrophobic PTFE: a non-contaminating surface10.1088/0022-3727/40/24/027 ↗
14. Synergistic effect of resveratrol and quercetin released from drug-eluting polymer coatings for endovascular devices10.1002/jbm.b.31894 ↗
15. New frontiers in cardiology: drug-eluting stents: Part I10.1161/01.CIR.0000069330.41022.90 ↗
16. New frontiers in cardiology: drug-eluting stents: Part II10.1161/01.CIR.0000069331.67148.2F ↗
17. Angioplasty triggers intracoronary leukotrienes and lipoxin A4 impact of aspirin therapy10.1161/01.CIR.86.1.56 ↗
18. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis10.1161/ATVBAHA.108.181750 ↗
19. International union of pharmacology XXXVII, nomenclature for leukotriene and lipoxin receptors10.1124/pr.55.1.8 ↗
20. Functional characteristics of cysteinyl-leukotriene receptor subtypes10.1016/S0024-3205(02)01733-2 ↗
21. Leukotriene receptors: crucial components in vascular inflammation
22. Leukotriene modifiers in the treatment of cardiovascular diseases10.1189/jlb.0808476 ↗
23. Platelets, neutrophils, and vasoconstriction after arterial injury by angioplasty in pigs: effects of MK-886, a leukotriene biosynthesis inhibitor10.1038/sj.bjp.0701611 ↗
24. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects10.1126/science.2820055 ↗
25. Leukotriene modifiers as potential therapeutics for cardiovascular disease10.1038/nrd1796 ↗
26. Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats10.1093/ejcts/ezs312 ↗
27. Optimization of chronomodulated delivery system coated with a blend of ethyl cellulose and eudragit L100 by central composite design. In vitro and in vivo evaluation10.1007/s12247-014-9176-3 ↗
28. Leukotriene biosynthesis inhibition ameliorates acute lung injury following hemorrhagic shock in rats10.1186/1749-8090-6-81 ↗
29. Protein encapsulated core-shell structured particles prepared by coaxial electrospraying: investigation on material and processing variables10.1016/j.ijpharm.2014.07.006 ↗
30. Controlled delivery of stromal derived factor-1α from poly lactic-co-glycolic acid core-shell particles to recruit mesenchymal stem cells for cardiac regeneration10.1016/j.jcis.2015.04.005 ↗
31. Electrospraying technique for the fabrication of metronidazole contained PLGA particles and their release profile10.1016/j.msec.2015.06.018 ↗
32. Thakur · 2015
33. Relationship between in vitro lipopolysaccharide-induced cytokine response in whole blood, angiographic in-stent restenosis, and toll-like receptor 4 gene polymorphisms10.1373/clinchem.2004.041277 ↗
34. Effects of various forms of lipopolysaccharide on the expression of inflammatory mediators and cardiac biomarkers in human cardiac fibroblasts and human coronary smooth muscle cells10.5897/AJB11.511 ↗
35. Role of cysteinyl leukotrienes in the proliferation and the migration of murine vascular smooth muscle cells in vivo and in vitro10.1016/j.cardiores.2007.05.018 ↗
36. Cysteinyl leukotriene D4 induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia10.1055/s-0038-1650530 ↗
37. Advances in drug delivery via electrospun and electrosprayed nanomaterials
38. Biodegradable and elastomeric poly(glycerol sebacate) as a coating material for nitinol bare stent
39. Electrohydrodynamic preparation of particles, capsules and bubbles for biomedical engineering applications10.1016/j.colsurfa.2010.11.038 ↗
40. Predictors of glass transition in the biodegradable poly-lactide and poly-lactide-co-glycolide polymers10.1002/app.22135 ↗
41. Restenosis after coronary angioplasty potential biologic determinants and role of intimal hyperplasia10.1161/01.CIR.79.6.1374 ↗
42. Pathophysiology of coronary artery restenosis
43. Suppression of intimal hyperplasia by a 5-lipoxygenase inhibitor, MK-886: studies with a photochemical model of endothelial injury10.1055/s-0037-1614959 ↗
44. The ACh-induced contraction in rat aortas is mediated by the Cys LT1 receptor via intracellular calcium mobilization in smooth muscle cells10.1038/sj.bjp.0705087 ↗
45. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability10.1073/pnas.0602414103 ↗
46. Influence of atherosclerosis on the vascular reactivity of isolated human epicardial coronary arteries to leukotriene C4
47. Functional characterization of cysteinyl leukotriene CysLT(2) receptor on human coronary artery smooth muscle cells10.1006/bbrc.2001.5695 ↗
48. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis10.1161/01.ATV.0000082690.23131.CB ↗
49. Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling10.1152/ajpheart.00143.2005 ↗
50. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS10.1016/S0008-6363(02)00512-6 ↗
51. Cysteinyl leukotriene signaling through perinuclear CysLT(1) receptors on vascular smooth muscle cells transduces nuclear calcium signaling and alterations of gene expression10.1007/s00109-012-0904-1 ↗
52. Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells10.1161/01.ATV.0000082689.46538.DF ↗
53. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia10.1073/pnas.0505845102 ↗